Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer.
Ontology highlight
ABSTRACT: Cisplatin (DDP) resistance limits therapeutic efficacy in patients diagnosed with ovarian cancer. Purvalanol A (Pur) is a novel cyclin-dependent kinase (CDK) inhibitor that has been demonstrated to induce apoptosis in various cancer cells. The present study investigated the effect of the combination treatment of Pur and DDP, and the potential anticancer mechanisms in epithelial ovarian cancer (EOC) cells in vitro and in vivo . We found that Pur enhanced the anti-tumor efficacy of cisplatin in EOC cells. The combination of Pur and DDP had more significant effects on apoptosis induction in EOC cells compared with the individual-treatment groups and the control group. We further demonstrated that the combination of Pur and DDP may trigger apoptosis and autophagy in EOC cells by inducing react
SUBMITTER: Zhang X
PROVIDER: S-EPMC9760476 | biostudies-literature | 2023 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA